Article

Journal of Cancer Education

, Volume 26, Issue 4, pp 664-669

Knowledge About Genomic Recurrence Risk Testing Among Breast Cancer Survivors

  • Isaac M. LipkusAffiliated withDuke University School of Nursing Email author 
  • , Susan T. VadaparampilAffiliated withMoffitt Cancer Center and Research Institute
  • , Paul B. JacobsenAffiliated withMoffitt Cancer Center and Research Institute
  • , Cheryl A. MireeAffiliated withMoffitt Cancer Center and Research Institute

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Genomic expression profiling of tumors is used to individualize early-stage breast cancer treatment. However, very little is known about patients’ understanding of and desired information about these tests, such as Oncotype DX. We addressed these issues via a survey mailed to 130 early-stage breast cancer patients who received an Oncotype DX test result. The survey assessed understanding (14 items), information desired about genomic expression profiling tests, and if and where they sought information about Oncotype DX. Sixty-four surveys were returned. Overall, 54% of the knowledge items were answered correctly. Patients wanted education about genomic tests in many areas. Overall, 62% sought information about the test, primarily from the Internet (48%) and doctor or health care provider (31%). In sum, patients’ misunderstanding of genomic tests abound, necessitating better educational efforts on behalf of health care systems to meet their needs for varied information through different communication channels.

Keywords

Breast cancer Genomic testing Knowledge Decision-making